Positron Corp. · OTC:POSC
Positron — Investor Presentation (September 2010)
27 slides from Positron's investor presentation, Sep 20, 2010
Slide 1: Investor Presentation September 2010
Patrick G. Rooney Chairman & CEO Investor Presentation September 2010 //
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation may constitute "forward-looking statements“. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or
Slide 3: Ticker Symbol
Ticker Symbol // POSC.OB Current Price // $0.06 52-week Range // $0.05 - $0.30 Shares Outstanding //| 773.4M Float // 390.0M Market Capitalization // $50 Million Positron
Slide 4: Positron Introduction
Positron Introduction A molecular imaging company focused on nuclear cardiology Positron Corporation offers a new perspective and unique solutions for cardiac imaging through the production and distribution of molecular imaging devices and radiopharmaceutical products
Slide 5: Positron Introduction
Positron Introduction Positron is made up of 2 segments based on its proprietary technologies: // Positron Emission Tomography (PET) imaging devices // Radiopharmaceuticals for PET & SPECT imaging // Automated unit dose delivery devices // Radiopharmaceuticals (consumables)
Slide 6: History (1983-2005)
History (1983-2005) // Formed in 1983 based on PET technologies designed by renowned cardiologist Dr. Gould of the University of Texas // One of only 4 companies in the world that manufacture PET systems (GE, Siemens, Phillips) // Research & development company that offered the best PET system devel
Slide 7: History (1983-2005)
History (1983-2005) // Under an unfavorable reimbursement policy and expensive PET systems failed to claim a significant market share in nuclear cardiology from an older and less expensive technology - SPECT // Tried to enter oncology imaging market but failed to compete with more expensive optimize
Slide 8: Transition Period: 2005-2010
Transition Period: 2005-2010 // 2005: New management, new capital, new strategy // Outsourced manufacturing/formed joint venture with leading medical equipment designer & manufacturer Neusoft Medical Systems (China) with a goal to develop state of the art PET system at a competitive price to meet th
Slide 9: Transition Period: 2005-2010
Transition Period: 2005-2010 // 2010 : strategic alliance with Covidien, one of the world largest manufacturers of radiopharmaceuticals, for development of an innovative distribution model of radiopharmaceuticals based on Positron’s devices // 2010 : acquired pharmaceutical manufacturing plant for d
Slide 10: Major Results
Major Results // Developed state of art PET scanner, the Attrius®, received FDA approval in 2009 // The Attrius® received Frost and Sullivan’s “Most Innovative Medical Device of the Year” award for 2010 // Sold 9 PET systems and expect to sell 4-6 more in 2010 40 in 2011 and 120 in 2012. All systems
Slide 11: Major Results
Major Results // Acquired full scale radiopharmaceutical manufacturing plant advances pharmaceutical growth plans 12 months ahead of schedule // In 2010, revenue is expected to be at least 4 times higher than in 2009 // Positron has recently satisfied all obligations and currently carries no debt
Slide 12: Positron Products
Positron Products
Slide 13: Attrius®
Attrius® // Only stand-alone PET scanner in the world. The Attrius® is optimized for cardiac imaging - the scanner of choice for nuclear cardiologists seeking high quality PET imagery and cardiovascular specific interpretation tools // Combines superior technology with Positron’s proprietary disease
Slide 14: Attrius®
Attrius® // Can also imagine oncology studies which makes it the right system for small market multimodality hospitals and imaging services // Significantly reduces radiation exposure compared to traditional PET/CT scanners // Positron has preferential pricing that gives competitive advantages to th
Slide 15: Positron Products
Positron Products Positron
Slide 16: Cardio-Assist™
Cardio-Assist™ // Proprietary automated radiopharmaceutical unit dose delivery device for on-site compounding and dispensing of radiopharmaceutical agents used in molecular imaging // Eliminates the need for a centralized radiopharmacy and multiple daily deliveries // Provides 24/7 availability of r
Slide 17: Cardio-Assist™
Cardio-Assist™ // A compounding aseptic contaminate isolator - a platform for governmental regulatory compliance guidelines such as USP 797 // Will provide Positron with recurring revenue from radiopharmaceutical agents used by imaging practices
Slide 18: Market Opportunity
Market Opportunity // Over 7,000+ nuclear imaging facilities - potential candidates for the evolution of PET imaging and direct distribution of radiopharmaceuticals // Nuclear Cardiology - a market demand is shifting from SPECT to PET: // Reimbursement policy recently switched in favor of PET // Wor
Slide 19: Market Opportunity
Market Opportunity // In U.S. there are 14,000 SPECT cameras and more than 800 replacement SPECT cameras installed every year (Global Industry Analysis, 2008), the Company’s conservative estimate of the market for dedicated cardiac PET scanners in U.S. is to exceed $1B in device sales over the next
Slide 20: Competitive Advantages
Competitive Advantages // Command of market/World leader in cardiac PET // Unique radiopharmaceutical distribution model // Proprietary technologies // Earlier adopter of the movement from SPECT to PET // Experienced PET and pharmaceutical team // Positron’s product lines directly address the intens
Slide 21: Core Focus
Core Focus // Core business focus - provide unique and innovative solutions for the nuclear cardiology community in molecular imaging technologies and radiopharmaceutical supply // Business objective - to become a sustained long term value creator for shareholders // Business strategy - to maximize
Slide 22: Growth Strategy
Growth Strategy // Explore additional strategic interests that advance PET imaging systems and radiopharmaceutical distribution // Evaluate all organic and strategic partnership opportunities // Engage in more robust business development opportunities // Cardiologist practices // Radiopharmaceutical
Slide 23: Estimated backlog of PET systems 2010-2012
Note: The estimated backlog is 6, 12 and 22 PET systems in 2010-2012
Slide 24: Revenue mix 2010 and 2013
2010 2013 Pharmaceuticals, 2.2% Service, Pharmaceuticals, 31.5% 5.3% Positron
Slide 25: Management Team
Technical Officer, Director of Clinical Programs, has served as a Director since 2005. Mr. Oliverio has been instrumental in guiding Positron’s PET technology. Mr. Oliverio is a Certified Nuclear Medicine Technologist and has performed over 13,000 cardiac and/or oncology scans, imaged with Positron
Slide 26: Investment Highlights
Investment Highlights // Attractive growth prospects driven by paradigm shift in in nuclear cardiology to more efficient imaging technologies (PET), better radiopharmaceutical supply and reduction of radiation exposure // Technology leadership/Products command their market // Recurring cash-generati
Slide 27: investor@positron.com 317.576.0183 www.positron.com
// // // investor@positron.com 317.576.0183 www.positron.com